Incannex Healthcare announced a company presentation containing data and analysis of the results from the Phase 1 clinical trial undertaken to assess safety and pharmacokinetics of IHL-675A as an anti-inflammatory drug candidate.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on IXHL:
- Incannex Company Presentation – Results from Phase 1 Clinical Trial to Assess Proprietary IHL-675A
- Incannex announces final results from Phase 1 trial assessing IHL-675A
- Incannex Announces Final Results from Phase 1 Clinical Trial Assessing Safety and Pharmacokinetics of IHL-675A
- PharmAla Biotech to supply Incannex with LaNEO MDMA, psilocybin
- Incannex appoints QPS to advance CannQuit-N, CannQuit-O, Renecann